Universitat de Girona
Now showing items 1-7 of 7
Pancreatic ductal adenocarcinoma (PDA) presents a dismal prognosis mainly due to its delayed diagnosis, its aggressiveness, and resistance to existing therapies. Aberrant glycosylation and, in particular, ...
Els pacients amb càncer presenten una taxa de supervivència superior si es diagnostiquen a estadis inicials, per la qual cosa és indispensable disposar de marcadors tumorals adequats. Glicoformes de ...
Pancreatic cancer (PaC) is the deadliest of all tumours, with a 5-year survival below 12% and a mortality/incidence ratio of 94.5%. One of the main reasons behind this dismal prognosis is the diagnosis ...
L'adenocarcinoma pancreàtic és una neoplàsia amb mal pronòstic per la que no existeixen marcadors específics. En aquesta tesi s'han estudiat possibles alteracions de les estructures glucídiques de la ...
Pancreatic Ductal Adenocarcinoma (PDA), the most common pancreatic cancer, remains one of the most lethal tumor types, with extremely low survival rates due to late diagnosis and resistance to standard ...
Cancer is one of the leading causes of death worldwide. Pancreatic ductal adenocarcinoma (PDAC) is characterized by high intrinsic aggressiveness and late diagnosis, causing poor prognosis and resulting ...
ENG- Pancreatic cancer (PDAC) is becoming more common, especially in developed countries, due to risk factors like smoking and alcohol-related chronic pancreatitis (CP). Its hidden location often causes ...
